Ocugen Has Completed Dosing In Third Cohort Of Phase 1/2 ArMaDa Trial For OCU410 (AAV-hRORA) For Geographic Atrophy, The Company Has Initiated Phase 2 Trial To Assess OCU410 In Larger Group Of Patients
Portfolio Pulse from Benzinga Newsdesk
Ocugen has completed dosing in the third cohort of its Phase 1/2 ArMaDa trial for OCU410 (AAV-hRORA) targeting geographic atrophy. The company has also initiated a Phase 2 trial to assess OCU410 in a larger group of patients.
July 25, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocugen has completed dosing in the third cohort of its Phase 1/2 ArMaDa trial for OCU410 and has initiated a Phase 2 trial to assess the treatment in a larger group of patients.
The completion of dosing in the Phase 1/2 trial and the initiation of a Phase 2 trial are positive developments for Ocugen, indicating progress in their clinical trials for OCU410. This could lead to increased investor confidence and a potential short-term rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100